4-aryl-imidazole derivatives
US5462959A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 14, 1993 |
| Grant date | Oct 31, 1995 |
| Priority date | — |
| Expiry date | Oct 14, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a 4-aryl-imidazole derivative having the formula I ##STR1## wherein X is 0 or NOH, PA0 Y is NR.sub.3, PA0 Ar is a group selected from phenyl, naphthyl, tetrahydronaphthyl, and biphenyl, PA0 R is one to four substituents independently selected from hydrogen, hydroxy, lower alkyl, lower alkoxy, lower thioalkyl, cycloalkyl, halogen, CF.sub.3, NO.sub.2, and O--ALK--NR.sub.1 R.sub.2, in which ALK is a saturated aliphatic hydrocarbon group having 2-6 carbon atoms, and R.sub.1 and R.sub.2 are independently hydrogen or lower alkyl, or form, together with the nitrogen atom to which they are bonded, a heterocyclic ring, and PA0 R.sub.3 is hydrogen or a lower alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that 4-(4-chlorophenyl)-thiazole-2-carboxamide is excluded. The compounds according to the invention increase the sensitivity of cardiac myofibrils to calcium and possess phosphodiesterase inhibitory activity and bronchodilator activity, and are useful for the treatment of patients suffering from heart failure and asthma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.